# Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment

> **NCT05780073** · PHASE2 · COMPLETED · sponsor: **Fundació Institut Germans Trias i Pujol** · enrollment: 60 (actual)

## Conditions studied

- HIV Infection Primary

## Interventions

- **DRUG:** Dasatinib 70 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05780073
- **Lead sponsor:** Fundació Institut Germans Trias i Pujol
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-16
- **Primary completion:** 2025-04-01
- **Final completion:** 2025-04-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05780073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05780073, "Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT05780073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*